Skip to main
TECH
TECH logo

Bio-Techne (TECH) Stock Forecast & Price Target

Bio-Techne (TECH) Analyst Ratings

Based on 11 analyst ratings
Buy
Strong Buy 36%
Buy 45%
Hold 18%
Sell 0%
Strong Sell 0%

Bulls say

Bio-Techne is projected to achieve $315.0 million in revenues, reflecting a 3% growth compared to the previous quarter, and adjusted earnings are expected to improve to $0.50 per share, an increase from $0.49 a year ago. The company predominantly operates within the protein sciences segment, contributing approximately 75% of its revenue, which underlies its strong position in the life sciences research market. With diversified operations across North America, Europe, the Middle East, and Asia-Pacific, Bio-Techne is well-positioned for sustained growth and resilience in the evolving biotech landscape.

Bears say

Bio-Techne, a Minnesota-based life sciences manufacturer, is facing potential negative impacts on its revenues and gross margins due to the escalation of US tariffs and proposed significant cuts in funding for key US agencies, such as the NIH. The company’s reliance on the US market, which accounts for approximately 55% of its revenue, heightens its vulnerability to these external economic pressures. As a result, there are adjustments to revenue and margin estimates for the upcoming fourth quarter of fiscal year 2025, indicating expectations of slower-than-anticipated performance.

Bio-Techne (TECH) has been analyzed by 11 analysts, with a consensus rating of Buy. 36% of analysts recommend a Strong Buy, 45% recommend Buy, 18% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Bio-Techne and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Bio-Techne (TECH) Forecast

Analysts have given Bio-Techne (TECH) a Buy based on their latest research and market trends.

According to 11 analysts, Bio-Techne (TECH) has a Buy consensus rating as of Oct 14, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $70.64, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $70.64, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Bio-Techne (TECH)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.